Jim Simons’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41.3M | Sell |
1,825,501
-58,500
| -3% | -$1.3M | 0.06% | 381 |
|
|
2025
Q4 | $48.8M | Sell |
1,884,001
-254,200
| -12% | -$6.04M | 0.08% | 307 |
|
|
2025
Q3 | $55.1M | Sell |
2,138,201
-257,400
| -11% | -$6.32M | 0.07% | 322 |
|
|
2025
Q2 | $57.3M | Buy |
2,395,601
+155,000
| +7% | +$3.91M | 0.08% | 293 |
|
|
2025
Q1 | $55.7M | Buy |
2,240,601
+248,000
| +12% | +$5.94M | 0.08% | 295 |
|
|
2024
Q4 | $37.5M | Buy |
1,992,601
+13,604
| +0.7% | +$239K | 0.06% | 419 |
|
|
2024
Q3 | $29.8M | Sell |
1,978,997
-87,200
| -4% | -$1.49M | 0.04% | 495 |
|
|
2024
Q2 | $59.1M | Buy |
2,066,197
+184,000
| +10% | +$5.24M | 0.1% | 238 |
|
|
2024
Q1 | $55M | Buy |
1,882,197
+165,500
| +10% | +$5.08M | 0.09% | 286 |
|
|
2023
Q4 | $57.9M | Buy |
1,716,697
+102,700
| +6% | +$3M | 0.09% | 265 |
|
|
2023
Q3 | $49.5M | Buy |
1,613,997
+39,300
| +2% | +$1.42M | 0.08% | 274 |
|
|
2023
Q2 | $63.1M | Buy |
1,574,697
+15,800
| +1% | +$653K | 0.09% | 249 |
|
|
2023
Q1 | $63.6M | Sell |
1,558,897
-28,200
| -2% | -$1.12M | 0.08% | 283 |
|
|
2022
Q4 | $61.3M | Sell |
1,587,097
-166,400
| -9% | -$8.1M | 0.08% | 271 |
|
|
2022
Q3 | $93.3M | Sell |
1,753,497
-212,000
| -11% | -$11.8M | 0.13% | 165 |
|
|
2022
Q2 | $115M | Buy |
1,965,497
+104,500
| +6% | +$6.85M | 0.14% | 165 |
|
|
2022
Q1 | $142M | Buy |
1,860,997
+11,800
| +0.6% | +$787K | 0.17% | 123 |
|
|
2021
Q4 | $111M | Sell |
1,849,197
-119,600
| -6% | -$6.59M | 0.14% | 160 |
|
|
2021
Q3 | $110M | Sell |
1,968,797
-91,530
| -4% | -$5.28M | 0.14% | 155 |
|
|
2021
Q2 | $125M | Sell |
2,060,327
-254,470
| -11% | -$16.1M | 0.16% | 124 |
|
|
2021
Q1 | $162M | Sell |
2,314,797
-310,262
| -12% | -$22.2M | 0.2% | 90 |
|
|
2020
Q4 | $157M | Sell |
2,625,059
-155,038
| -6% | -$9.08M | 0.17% | 111 |
|
|
2020
Q3 | $167M | Sell |
2,780,097
-70,700
| -2% | -$4.11M | 0.17% | 113 |
|
|
2020
Q2 | $150M | Buy |
2,850,797
+382,655
| +16% | +$16M | 0.13% | 155 |
|
|
2020
Q1 | $82.8M | Buy |
2,468,142
+670,804
| +37% | +$27.9M | 0.08% | 253 |
|
|
2019
Q4 | $81.4M | Buy |
1,797,338
+582,238
| +48% | +$24.7M | 0.06% | 350 |
|
|
2019
Q3 | $46.3M | Buy |
1,215,100
+122,900
| +11% | +$4.91M | 0.04% | 532 |
|
|
2019
Q2 | $47.5M | Buy |
1,092,200
+28,600
| +3% | +$1.21M | 0.04% | 514 |
|
|
2019
Q1 | $40.5M | Buy |
1,063,600
+708,300
| +199% | +$27.6M | 0.04% | 609 |
|
|
2018
Q4 | $15.3M | Buy |
355,300
+280,995
| +378% | +$13.1M | 0.02% | 1057 |
|
|
2018
Q3 | $3.65M | Buy |
+74,305
| New | +$3.21M | ﹤0.01% | 1983 |
|
|
2018
Q1 | – | Sell |
-509,900
| Closed | -$23.3M | – | 3521 |
|
|
2017
Q4 | $23.3M | Buy |
509,900
+135,400
| +36% | +$5.37M | 0.03% | 846 |
|
|
2017
Q3 | $14.1M | Buy |
374,500
+356,700
| +2,004% | +$14.4M | 0.02% | 1119 |
|
|
2017
Q2 | $849K | Buy |
+17,800
| New | +$826K | ﹤0.01% | 2619 |
|
|
2017
Q1 | – | Sell |
-25,200
| Closed | -$814K | – | 3362 |
|
|
2016
Q4 | $814K | Buy |
25,200
+400
| +2% | +$13.3K | ﹤0.01% | 2623 |
|
|
2016
Q3 | $849K | Sell |
24,800
-10,000
| -29% | -$392K | ﹤0.01% | 2639 |
|
|
2016
Q2 | $1.17M | Buy |
+34,800
| New | +$1.71M | ﹤0.01% | 2469 |
|
|
2015
Q4 | – | Sell |
-108,500
| Closed | -$4.46M | – | 3392 |
|
|
2015
Q3 | $4.46M | Buy |
+108,500
| New | +$6.65M | 0.01% | 1471 |
|
|
2015
Q1 | – | Sell |
-9,800
| Closed | -$869K | – | 3307 |
|
|
2014
Q4 | $869K | Sell |
9,800
-30,000
| -75% | -$2.84M | ﹤0.01% | 2192 |
|
|
2014
Q3 | $3.86M | Buy |
+39,800
| New | +$3.87M | 0.01% | 1296 |
|
|
2014
Q2 | – | Sell |
-171,500
| Closed | -$12M | – | 2921 |
|
|
2014
Q1 | $12M | Buy |
171,500
+100,000
| +140% | +$6.8M | 0.03% | 766 |
|
|
2013
Q4 | $4.11M | Buy |
+71,500
| New | +$3.76M | 0.01% | 1307 |
|
Other funds holding PCRX
DPCM
VPM
VCM
Jim Simons's PCRX Position: Q1 2026 in Review
Jim Simons reduced its Pacira BioSciences (PCRX) stake by 3.1% in Q1 2026, selling an estimated $1.3M and leaving 1,825,501 shares worth $41.3M. The position accounts for 0.06% of the portfolio, ranked #381.
Jim Simons first reported a position in PCRX in Q4 2013 and has held it in 42 quarters since. The position peaked at $167M in Q3 2020. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- Jim Simons held 1,825,501 shares of Pacira BioSciences worth $41.3M as of Q1 2026.
- Jim Simons sold 58,500 Pacira BioSciences shares in Q1 2026, an estimated $1.3M.
- Pacira BioSciences made up 0.06% of Jim Simons's portfolio in Q1 2026, its #381 holding.
- Jim Simons first reported a position in Pacira BioSciences in Q4 2013 and has held it in 42 quarters since.
- Jim Simons's Pacira BioSciences position peaked at $167M in Q3 2020.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.